OverviewSuggest Edit

Santen is a specialized pharmaceutical company focusing on ophthalmology. It provides a range of therapies to address glaucoma, dry eye, allergy, cataract, astigmatism, diabetic retinopathy, muscae volitantes, and other medical conditions.
HQOsaka, JP
Employee Ratings3.5

Latest Updates

Employees (est.) (Mar 2019)4,073
Job Openings45
Share Price (Sept 2021)¥1.7 K
Cybersecurity ratingBMore

Key People/Management at Santen

Akira Kurokawa

Akira Kurokawa

Representative Director of the Board, Chairman
Shigeo Taniuchi

Shigeo Taniuchi

Representative Director of the Board, President, Chief Executive Officer
Takeshi Ito

Takeshi Ito

Director of the Board, Executive Corporate Officer, Head of Japan Business, Head of Japan Sales & Marketing Division
Kanoko Oishi

Kanoko Oishi

Director of the Board
Kazuo Koshiji

Kazuo Koshiji

Senior Corporate Officer, Corporate Administration, Chief Financial Officer(CFO), Head of Finance and Administration Division
Minori Hara

Minori Hara

Corporate Officer, Chief Information Officer (CIO), Head of Information Systems Division
Show more

Santen Office Locations

Santen has offices in Osaka, Hodatsushimizu, Ikoma, Emeryville and in 17 other locations
Osaka, JP (HQ)
4-20 Ōfukachō, Kita-ku
Ikoma, JP
Osaka, JP
3 Chome Shimoshinjo, Higashiyodogawa Ward
Suzhou Shi, CN
Xinghua St, Wuzhong Qu
Tampere, FI
Niittyhaankatu 20
Vantaa, FI
Karhumäenkuja 3
Show all (30)

Santen Financials and Metrics

Santen Revenue

Market capitalization (9-Sept-2021)


Closing stock price (9-Sept-2021)

Santen's current market capitalization is ¥678.6 b.
Show all financial metrics

Santen Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Santen Online and Social Media Presence

Embed Graph

Santen News and Updates

Global Allergic Conjunctivitis Market (2020 to 2027) - Featuring Santen Pharmaceutical, Alcon, Portola Pharmaceuticals and Ocular Therapeutix Among Others

Dublin, April 13, 2021 (GLOBE NEWSWIRE) -- The "Allergic Conjunctivitis Market, Global Forecast Treated Patients By Countries, Disease Type, Pipeline Drugs, Company Analysis" report has been added to ResearchAndMarkets.com's offering. Allergic conjunctivitis is common ophthalmic disorder caused by…

Santen Announces Global Research Initiative with Massachusetts Eye and Ear and Ulster University Researchers to Study and Develop New Treatments for Glaucoma

GENEVA and EMERYVILLE, Calif., April 12, 2021 /PRNewswire/ -- Santen, a global company specialized in ophthalmology, today announced a research initiative with scientists from Massachusetts (Mass) Eye and Ear (USA), a research and teaching hospital affiliated with Harvard Medical School,...

Santen Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for Cyclosporine Topical Ophthalmic Emulsion, 0.1% for the Treatment of Severe Vernal Keratoconjunctivitis in Patients Ages 4-18

EMERYVILLE, Calif., Oct. 26, 2020 /PRNewswire/ -- Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. (hereinafter, Santen), a global company focused exclusively on ophthalmology, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug...

Santen and Orbis International Announce Long-term Partnership to Tackle the Increasing Burden of Eye Diseases

NEW YORK, Oct. 7, 2020 /PRNewswire/ -- Santen Pharmaceutical Co., Ltd. (hereinafter, Santen) and Orbis International (hereinafter, Orbis) today announced a long-term, ten-year partnership to tackle the increasing burden of eye diseases in low- and middle-income countries, especially in...

Santen and RVL Pharmaceuticals, Inc., an Osmotica Company, Enter into an Exclusive License Agreement in Japan, Asia, and EMEA for RVL-1201, a First-in-Class Treatment for Acquired Blepharoptosis

OSAKA, Japan and BRIDGEWATER, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd (hereinafter, Santen) and RVL Pharmaceuticals, Inc., a subsidiary of Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (hereinafter, Osmotica), announced today an exclusive license agreement covering the…

Santen Announces U.S. FDA Acceptance of Premarket Approval (PMA) Application for DE-128 (MicroShunt) for Review

OSAKA, Japan, July 6, 2020 /PRNewswire/ -- Santen Pharmaceutical Co., Ltd. (hereinafter, Santen) today announced that the United States Food and Drug Administration (FDA) has accepted the Premarket Approval (PMA) application for DE-128 (MicroShunt) for review. DE-128 is an investigational...
Show more

Santen Frequently Asked Questions

  • When was Santen founded?

    Santen was founded in 1890.

  • Who are Santen key executives?

    Santen's key executives are Akira Kurokawa, Shigeo Taniuchi and Takeshi Ito.

  • How many employees does Santen have?

    Santen has 4,073 employees.

  • Who are Santen competitors?

    Competitors of Santen include Opthea, EMS Pharma and Livzon Pharmaceutical Group.

  • Where is Santen headquarters?

    Santen headquarters is located at 4-20 Ōfukachō, Kita-ku, Osaka.

  • Where are Santen offices?

    Santen has offices in Osaka, Hodatsushimizu, Ikoma, Emeryville and in 17 other locations.

  • How many offices does Santen have?

    Santen has 30 offices.